

AMENDMENTS TO THE CLAIMS

Claim 1. (Previously Presented) A method for the treatment of one or more of (a) non-inflammatory bowel disease, (b) diverticulosis, (c) diverticulitis, (d) diarrhoea-predominant irritable bowel syndrome, (e) irritable bowel syndrome, (f) one or more of bloating, diarrhoea, cramping, pain, low abdominal pain, distension, wind, flatulence, gas production, fluid secretion, mucus production, constipation, urgency or incontinence, when associated with a non-inflammatory bowel disease, diarrhoea-predominant irritable bowel syndrome or other non-specific non-inflammatory bowel disorder, (g) non ulcer dyspepsia, (h) spastic colon, (i) unstable colonic neurosis, (j) spastic colitis, (k) mucous colitis, (l) alternating constipation/diarrhoea, (m) alternating diarrhoea and constipation type IBS or (n) constipation IBS, comprising administering to a patient in need of such treatment an effective amount of balsalazide or a salt thereof or a composition comprising balsalazide or a salt thereof together with a suitable carrier.

Claim 2. (original) A method according to claim 1 wherein the method alleviates symptoms of alternating diarrhoea and constipation type Irritable Bowel Syndrome or constipation predominant Irritable Bowel Syndrome.

Claim 3. (cancelled)

Claim 4. (original) A method according to claim 1 wherein the patient is a mammal.

Claim 5. (original) A method according to claim 4 wherein the patient is a human.

Claim 6. (Previously Presented) A method according to claim 1 wherein balsalazide is administered together with one or more of a 4-aminosalicylic acid or 5-aminosalicylic acid compound.

Claim 7. (Previously Presented) A method according to claim 6 wherein the 5-aminosalicylic acid or 4-aminosalicylic acid compound is mesalazine, olsalazine, sulfasalazine,

ipsalazide, benzalazine, para-amino salicylic acid and pharmaceutically acceptable salts thereof.

Claim 8. (Currently Amended) A method according to claim 1 wherein balsalazide is administered together with olsalazine for the treatment of ~~prophylaxis of~~ diarrhoea predominant, constipation predominant or alternating diarrhoea and constipation type Irritable Bowel Syndrome.

Claim 9. (Currently Amended) A method according to claim 1 wherein balsalazide is administered together with mesalazine for the treatment of ~~prophylaxis of~~ diarrhoea predominant Irritable Bowel Syndrome.

Claim 10. (original) A method according to claim 1 wherein the balsalazide is administered together with anti-cholinergics, probiotics, antibiotics or anti-spasm medications.

Claim 11. (Previously Presented) A method for the treatment of one or more of (a) non-inflammatory bowel disease, (b) diverticulosis, (c) diverticulitis, (d) diarrhoea-predominant irritable bowel, syndrome, (e) irritable bowel syndrome, (f) one or more of bloating, diarrhoea, cramping, pain, low abdominal pain, distension, wind, flatulence, gas production, fluid secretion, mucus production, constipation, urgency or incontinence, when associated with a non-inflammatory bowel disease, diarrhoea-predominant irritable bowel syndrome or other non-specific non-inflammatory bowel disorder, (g) non ulcer dyspepsia, (h) spastic colon, (i) unstable colonic neurosis, (j) spastic colitis, (k) mucous colitis, (l) alternating constipation/diarrhoea, (m) alternating diarrhoea and constipation type IBS or (n) constipation IBS, comprising administering to a patient in need of such treatment an effective amount of a 4-aminosalicylic acid or 5-aminosalicylic acid compound, the 4-aminosalicylic acid or 5-aminosalicylic acid compound each modified to include a 4-aminobenzoyl- β -alanine side chain, or a salt thereof or a composition comprising the compound or a salt thereof together with a suitable carrier.

Claims 12-13. (cancelled)